

Open

Randomized Trial of Prophylactic Antibiotics for Endoscopic Retrograde Cholangiopancreatography in Patients With Biliary Obstruction

Galam Leem, MD, PhD^{1,2}, Min Je Sung, MD³, Ji Hoon Park, MD⁴, So Jeong Kim, MD⁵, Jung Hyun Jo, MD, PhD^{1,2}, Hee Seung Lee, MD, PhD^{1,2}, Nam Su Ku, MD, PhD⁶, Jeong Youp Park, MD, PhD^{1,2}, Seungmin Bang, MD, PhD^{1,2}, Seung Woo Park, MD, PhD^{1,2}, Si Young Song, MD, PhD^{1,2} and Moon Jae Chung, MD, PhD^{1,2}

INTRODUCTION: The incidence of postendoscopic retrograde cholangiopancreatography (ERCP) infections is reported to be up to 18% in patients with biliary obstruction. Antibiotic prophylaxis may reduce the risk of infectious complications after ERCP; however, the clinical value of prophylactic antibiotics in ERCP remains controversial.

METHODS: We conducted a double-blind, placebo-controlled, randomized trial to investigate whether the use of prophylactic antibiotics would reduce infectious complications after ERCP in patients with biliary obstruction. We randomly assigned patients in a 1:1 ratio to receive either a single dose of 1 g intravenous cefoxitin or normal saline as a placebo 30 minutes before undergoing ERCP. The primary outcome was the incidence of infectious complications after ERCP.

RESULTS: We enrolled 378 patients, and 189 patients were assigned to each group. The risk of infectious complications after ERCP was 2.8% (5 of 176 patients) in the antibiotic prophylaxis group and 9.8% (17 of 173 patients) in the placebo group (risk ratio, 0.29; 95% confidence interval [CI], 0.11–0.74, $P = 0.0073$). The incidence rates of bacteremia were 2.3% (4 of 176 patients) and 6.4% (11 of 173 patients), respectively (risk ratio, 0.36; 95% CI, 0.12–1.04; $P = 0.0599$). The incidence rate of cholangitis was 1.7% (3 of 176 patients) in the antibiotic prophylaxis group and 6.4% (11 of 173 patients) in the placebo group (risk ratio, 0.27; 95% CI, 0.08–0.87; $P = 0.0267$).

DISCUSSION: Antibiotic prophylaxis before ERCP in patients with biliary obstruction resulted in a significantly lower risk of infectious complications, especially cholangitis, than placebo (ClinicalTrials.gov trial number NCT02958059).

KEYWORDS: endoscopic retrograde cholangiopancreatography (ERCP); post-ERCP complication; prophylactic antibiotics; post-ERCP bacteremia; post-ERCP cholangitis

SUPPLEMENTARY MATERIAL accompanies this paper at <http://links.lww.com/AJG/D41>, <http://links.lww.com/AJG/D42>

Am J Gastroenterol 2024;119:183–190. <https://doi.org/10.14309/ajg.0000000000002495>

INTRODUCTION

Endoscopic retrograde cholangiopancreatography (ERCP) is the gold standard for the diagnosis and treatment of patients with biliary obstruction (1). Because several procedures, including cannulation of the ampulla of Vater, endoscopic sphincterotomy, extraction of stones or sludges in bile ducts, intraductal biopsies, and palliative stenting, are performed using ERCP for patients with

biliary obstruction, ERCP is considered a high-risk procedure that can cause various complications. Infection is the most common complication associated with pancreatitis and bleeding, accounting for 10% of deaths from complications after ERCP (2–5). The incidence rate of post-ERCP infection, including bacteremia, cholangitis, and cholecystitis, is reported to be approximately 5%, but it increases to 18% in the setting of biliary obstruction (2,6–8).

¹Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; ²Institute of Gastroenterology Research, Yonsei University College of Medicine, Seoul, Korea; ³Digestive Disease Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea; ⁴Division of Gastroenterology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Gyeonggi-do, Korea; ⁵Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea; ⁶Division of Infectious Diseases, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. **Correspondence:** Moon Jae Chung, MD, PhD. E-mail: mjchung@yuhs.ac.

Received March 9, 2023; accepted August 29, 2023; published online September 15, 2023

In addition to the infectious complications from the procedure itself, patients undergoing ERCP are also susceptible to duodenoscope-related transmission of infection because of the challenge of duodenoscope reprocessing (5,9). In 2015, a post-ERCP carbapenem-resistant Enterobacteriaceae infection outbreak occurred at a medical center in the United States. Seven patients were infected with multidrug-resistant (MDR) bacteria, and 2 of them died. The Centers for Disease Control and Prevention in the United States has announced that this outbreak of carbapenem-resistant Enterobacteriaceae infection after ERCP was associated with a contaminated duodenoscope. A subsequent meta-analysis, including 15 studies and 13,112 samples, revealed that the contamination rate of reprocessed patient-ready duodenoscopes was 15.25% (10).

The clinical value of prophylactic antibiotics in preventing infectious complications after ERCP remains controversial. Several randomized controlled studies have reported that the prophylactic use of antibiotics reduced the incidence of bacteremia, but not cholangitis (11–14). A meta-analysis of 7 trials and a total of 1,389 patients showed that prophylactic antibiotics did not significantly prevent ERCP-induced cholangitis in unselected patients (15). However, in studies of patients with suspected biliary obstruction, prophylactic antibiotics showed potential preventive effects on post-ERCP cholangitis (13,16,17). A Cochrane Database of Systematic Review, including 9 randomized trials and 1,573 patients, has reported that prophylactic antibiotics reduce bacteremia and seem to prevent post-ERCP cholangitis and septicemia, but the effect is less evident in patients with uncomplicated ERCP (18). Based on these results, major international endoscopic societies, including the American Society for Gastrointestinal Endoscopy, the European Society of Gastrointestinal Endoscopy, and the British Society of Gastroenterology, do not recommend periprocedural antibiotic prophylaxis in ERCP except for the cases of anticipated incomplete biliary drainage and for severely immunocompromised patients (19–21). However, owing to the low quality of evidence, the level of recommendation is not strong, and further studies on high-risk patient groups are required (22).

We designed this single-center, double-blind, placebo-controlled, randomized trial (Prophylactic Antibiotics in ERCP for Biliary Obstruction) to investigate whether the use of prophylactic antibiotics (intravenous cefoxitin [second-generation cephalosporin] 1 g, once 30 minutes before ERCP) would reduce the infectious complications after ERCP in patients with biliary obstruction.

METHODS

Trial patients

The Prophylactic Antibiotics in ERCP for Biliary Obstruction trial was approved by the Institutional Review Board of the Yonsei University Medical Center (number 4-2015-0596). Patients were recruited at the Yonsei University Severance Hospital (Seoul, Korea) between April 2017 and February 2021. Patients whose biliary obstruction was radiologically confirmed using either computed tomography or magnetic resonance imaging and older than 19 years were eligible for inclusion and were scheduled to undergo ERCP for the diagnosis and treatment of radiologically confirmed biliary obstruction. Patients were ineligible if they were younger than 19 years, pregnant, allergic to beta-lactam antibiotics, or did not consent to this trial. Patients were also excluded from the trial if there was any evidence of infection (leukocytosis [white blood cells] $\geq 11,000/\text{mm}^3$, fever [$\geq 38^\circ\text{C}$], and history of empiric antibiotics for any kind of

infection) within 72 hours before ERCP. Written informed consent was obtained from all patients before randomization. This study was registered at ClinicalTrials.gov (NCT02958059).

Trial design

The enrolled patients were randomly assigned in a 1:1 ratio to receive either antibiotics or normal saline as a placebo 30 minutes before the ERCP procedure. In collaboration with an infectious disease specialist, we chose cefoxitin, a second-generation cephalosporin antibiotic, as a prophylactic antibiotic based on the recommendations for prophylaxis in biliary tract surgery or invasive procedures (23–25). We analyzed the results of antibiotic susceptibility tests for common bile bacteria (*Escherichia coli*, *Klebsiella pneumoniae*, etc), which were commonly detected in patients' blood cultures after ERCP in the same hospital for the past 2 years (2015–2017) and confirmed that cefoxitin would be effective against most of the detected strains. The antibiotic mixture (1 g of cefoxitin [Pacetin, JW Pharmaceutical, Seoul, Korea] in 10 mL of normal saline) or placebo (10 mL of normal saline) was prepared in the same syringe with the same label and administered to the patient through the same route by a pharmacist who was masked to the contents of the syringe. In all these processes, the assigned group of patients was unknown to the trial staff, endoscopists, and patients. During ERCP, the complete biliary drainage was defined as the resolution of the radiologically confirmed biliary obstructive lesion. After the ERCP procedure was completed, blood samples were collected for culture from all the enrolled patients as soon as possible after confirming the patient's recovery from moderate sedation during the procedure.

Outcome measures

The primary outcome was the incidence of infectious complications after ERCP, including bacteremia, cholangitis, and cholecystitis. Blood samples were collected from all enrolled patients within 24 hours after ERCP, and bacteremia was diagnosed when any of the bacterial strains were detected within 5 days of the culture of blood samples. Culture results of possible contamination like isolation of coagulase-negative staphylococcus in only 1 blood culture bottle were excluded. Post-ERCP cholangitis was diagnosed as the presence of 3 or more of the following 4 clinical features: aggravated right upper-quadrant abdominal pain, pyrexia ($>38.0^\circ\text{C}$ according to ear thermometry), inflammatory signs (white blood cell count $> 10,400/\mu\text{L}$ or C-reactive protein $> 8\text{ mg/L}$ or aggravated if they were already higher than the upper normal limit [UNL] before the procedure), jaundice (total bilirubin $> 2.0\text{ mg/dL}$ or aggravated if it was already higher than the UNL before the procedure), or abnormal liver function (gamma-glutamyl transferase, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase $>1.5 \times \text{UNL}$, or aggravated if they were already higher than the UNL before the procedure). Post-ERCP cholecystitis was diagnosed using additional radiologic tests, including abdominal ultrasonography or computed tomography, when there were clinically suspicious features. These criteria were derived from Tokyo guidelines (26). The incidence of each infectious complication was measured as a secondary outcome. In addition, the incidence of ERCP complications other than infection, such as bleeding and pancreatitis, was also analyzed as secondary outcomes. Post-ERCP pancreatitis was diagnosed when the patient developed symptoms of acute pancreatitis (i.e., abdominal pain) in addition to elevation of pancreatic enzymes (27).

Statistical analysis

The planned sample size of 400 patients was estimated using an inequality test for 2 independent proportions (PASS version 12, NCSS, LLC, UT) to provide 80% power to detect a relative difference between groups in the risk of infectious complications (risk ratio, 0.50) (14,18) under the assumption of a 2-sided *P* value of 0.05 and a 10% dropout rate. All analyses were performed in accordance with the intention-to-treat principle. Continuous variables were tested for normal distribution using the D’Agostino–Pearson normality test and analyzed using either an unpaired *t* test or the Mann–Whitney *U* test according to the result. For categorical variables, we used either the Fisher exact test or the χ^2 test according to the expected frequency of each cell for statistical analysis. The Koopman asymptotic score was used to calculate the confidence interval for the relative risk ratio. Statistical analyses were performed using Prism software V.8.4.3 (GraphPad, La Jolla, CA). *P* < 0.05 was considered significant.

RESULTS

Trial population

From April 2017 to February 2021, 400 patients were assessed for eligibility, and 378 patients underwent randomization. A total of 189 patients were assigned to receive antibiotic prophylaxis and 189 to receive a placebo. After withdrawal and exclusion, 176 patients in the antibiotic prophylaxis group and 173 patients in the placebo group were included in the outcome analysis. The patient enrollment, randomization, follow-up, and reasons for exclusion are shown in Figure 1.

The baseline characteristics of the patients were similar between the antibiotic prophylaxis and placebo groups (Table 1). Over 70% of the patients in each group showed symptoms, including jaundice, fever, chills, abdominal pain, and general weakness, and more than 70% of them had never undergone ERCP before. Malignant biliary obstruction was 44.9% in the

antibiotic prophylaxis group and 50.1% in the placebo group. In addition, malignant hilar obstruction was 15.3% in the antibiotic prophylaxis group and 10.4% in the placebo group. There were no significant differences in ERCP procedures, including total procedure time, amount of contrast dye used, procedures performed during ERCP, and the result of biliary drainage, between the antibiotic prophylaxis and placebo groups (Table 2). Complete biliary drainage was performed successfully in most patients, with a success rate of 91.5% in the antibiotic prophylaxis group and 90.9% in the placebo group.

Primary outcome

The incidence rate of infectious complications after ERCP was 2.8% (5 of 176 patients) in the antibiotic prophylaxis group and 9.8% (17 of 173 patients) in the placebo group (risk ratio, 0.29; 95% confidence interval [CI], 0.11–0.74, *P* = 0.0073) (Table 3).

Secondary outcomes

The incidence rate of bacteremia diagnosed with blood cultures within 24 hours after ERCP was 2.3% (4 of 176 patients) in the antibiotic prophylaxis group, as compared with 6.4% (11 of 173 patients) in the placebo group (risk ratio, 0.36; 95% CI, 0.12–1.04; *P* = 0.0599). The median time interval from ERCP to blood culture was 1 hour and 1 minute (interquartile range [IQR] of 59 minutes). There was no significant difference in the time interval of blood culture between the 2 groups (median time interval \pm IQR, 59 \pm 51 minutes in the antibiotic prophylaxis group and 1 \pm 1 hour 3 minutes in the placebo group; *P* value = 0.2231). Furthermore, there was also no significant difference in the time interval between patients with and without bacteremia (median time interval \pm IQR, 56 minutes \pm 1 hour 8 minutes and 1 hour 1 minute \pm 57 minutes, respectively; *P* value = 0.9570). Notably, of the 15 patients diagnosed with post-ERCP bacteremia, 10 (66.7%) developed septicemia and required treatment. The incidence rate of cholangitis diagnosed using the Tokyo guideline-based criteria




Figure 1. Trial profile. Summarized flow of enrollment, randomization, follow-up, and outcomes. ERCP, endoscopic retrograde cholangiopancreatography.

Table 1. Characteristics of the trial patients at baseline

Variables	Antibiotic prophylaxis (N = 176)	Placebo (N = 173)	P value
Age (yr)	65.1 ± 13.4	66.5 ± 12.0	0.6834
Sex			0.1729
Male	91 (51.7)	102 (59.0)	
Female	85 (48.3)	71 (41.0)	
Underlying disease	128 (72.7)	131 (75.7)	0.5225
HTN	77 (43.8)	87 (50.3)	
DM	46 (26.1)	55 (31.8)	
Heart disease	11 (6.3)	19 (11.0)	
Liver disease	7 (4.0)	5 (2.9)	
s/p liver transplantation	4 (2.3)	0 (0.0)	
COPD	0 (0.0)	2 (1.2)	
Malignancies	28 (15.9)	24 (13.9)	
Primary sclerosing cholangitis	1 (0.6)	0 (0.0)	
Others	49 (27.8)	54 (31.2)	
Previous ERCP			0.8613
No	137 (77.8)	136 (78.6)	
Yes	39 (22.2)	37 (21.4)	
Reason for ERCP			0.9051
Diagnostic	62 (35.2)	62 (35.8)	
Therapeutic	114 (64.8)	111 (64.2)	
Initial clinical manifestations			0.8275
Asymptomatic	46 (26.1)	47 (27.2)	
Symptomatic	130 (73.9)	126 (72.8)	
Laboratory tests before ERCP			
WBC ($\times 10^3/\mu\text{L}$)	6.37 ± 1.88	6.60 ± 2.27	0.4537
Total bilirubin (mg/dL)	3.9 ± 5.2	4.4 ± 6.0	0.3507
γ -GT (IU/L)	550.0 ± 573.6	526.9 ± 550.4	0.8570
ALP (IU/L)	265.7 ± 267.2	297.2 ± 275.6	0.2132
AST (IU/L)	111.6 ± 131.1	122.3 ± 216.3	0.6855
ALT (IU/L)	134.6 ± 165.7	137.6 ± 172.7	0.7127
CRP (mg/L)	13.3 ± 23.1	14.3 ± 29.5	0.2839
Reason for biliary obstruction			0.2634
Benign	97 (55.1)	85 (49.1)	
Post-LT anastomotic site stricture	4 (2.3)	0 (0.0)	
Malignancy	79 (44.9)	88 (50.1)	
Malignant hilar obstruction	27 (15.3)	18 (10.4)	0.1698

Data are presented as n (%) or mean ± SD.
Patients with post-LT anastomotic site strictures are also included in benign biliary obstruction.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COPD, chronic obstructive pulmonary disease; CRP, c-reactive protein; DM, diabetes mellitus; ERCP, endoscopic retrograde cholangiopancreatography; HTN, hypertension; IU, international unit.

was 1.7% (3 of 176 patients) in the antibiotic prophylaxis group and 6.4% (11 of 173 patients) in the placebo group (risk ratio, 0.27; 95% CI, 0.08–0.87; $P = 0.0267$). Only 1 patient in the trial who was assigned in the placebo group was diagnosed with post-ERCP cholecystitis. Two patients in the antibiotic prophylaxis

group and 6 patients in the placebo group showed multiple infectious complications. Other outcomes, including post-ERCP bleeding and pancreatitis, did not differ between the 2 groups (Table 3). The bacterial species identified in patients diagnosed with bacteremia are presented in Table 4.

Table 2. ERCP procedure characteristics

Variables	Antibiotic prophylaxis (N = 176)	Placebo (N = 173)	P value
Total procedure time (min)	19.0 ± 9.9	19.1 ± 11.0	0.5812
Contrast dye (mL)	15.8 ± 11.4	16.5 ± 12.8	0.7769
Performed procedure during ERCP			
Cannulation of bile duct	169 (96.0)	167 (94.9)	0.8017
Cannulation of pancreatic duct	26 (14.8)	20 (11.4)	0.3751
Bile duct sphincterotomy	130 (73.9)	123 (69.9)	0.5630
Pancreatic duct sphincterotomy	2 (1.1)	4 (2.3)	0.4457
Stone removal	77 (43.8)	69 (39.2)	0.4642
Balloon dilatation	57 (32.4)	58 (33.0)	0.8208
Bile duct stent insertion	94 (53.4)	101 (57.4)	0.3496
Plastic stent	81 (46.0)	83 (47.2)	
Metal stent	11 (6.3)	17 (9.7)	
ENBD	2 (1.1)	1 (0.6)	
Pancreatic duct stent insertion	14 (8.0)	8 (4.5)	0.2006
Plastic stent	13 (7.4)	8 (4.5)	
ENPD	1 (0.6)	0 (0.0)	
Biopsy/cytology of bile duct	54 (30.7)	46 (26.1)	0.3979
Biopsy/cytology of pancreatic duct	2 (1.1)	4 (2.3)	0.4457
Ampullectomy	2 (1.1)	2 (1.1)	>0.9999
Biliary drainage result			0.8281
No drainage	9 (5.1)	9 (5.1)	
Complete	161 (91.5)	160 (90.9)	
Incomplete	6 (3.4)	4 (2.3)	

Data are presented as n (%) or mean ± SD.
ERCP, endoscopic retrograde cholangiopancreatography; ENBD, endoscopic nasobiliary drainage; ENPD, endoscopic nasopancreatic drainage.

Subgroup analyses

We analyzed the primary and secondary outcomes in each subgroup divided according to the cause of biliary obstruction: malignant or benign. We found that fewer patients in the antibiotic prophylaxis group than in the placebo group suffered from infectious complications, regardless of the cause of biliary obstruction, and a statistically significant difference was confirmed in the incidence of cholangitis in the benign disease group ($P = 0.0421$) (see Supplementary Table S1, <http://links.lww.com/AJG/D42>).

We also confirmed that in patients with successfully performed biliary drainage by ERCP, prophylactic antibiotics significantly lowered the incidence of post-ERCP infectious complications (risk ratio, 0.29; 95% CI, 0.11–0.74; $P = 0.0077$) (see Supplementary Table S2, <http://links.lww.com/AJG/D42>). In the analysis of all patients, the incidence rate of bacteremia and cholangitis was reduced in the antibiotic prophylaxis group compared with the placebo group, of which the incidence of cholangitis showed a statistically significant difference (risk ratio, 0.27; 95% CI, 0.08–0.88; $P = 0.0279$).

Risk factor analyses

In the placebo group, repeated ERCP (risk ratio 2.57; 95% CI, 1.06–6.02; $P = 0.0566$) and performing procedures inducing

mechanical damage to the bile ducts during ERCP, such as stone removal (risk ratio 2.15; 95% CI, 0.89–5.23; $P = 0.0931$) and balloon dilatation (risk ratio 2.23; 95% CI, 0.93–5.31; $P = 0.0741$), had tendency toward increasing the risk of infectious complications after ERCP (Figure 2).

In the antibiotic prophylaxis group, we evaluated the risk factors associated with post-ERCP infectious complications. However, owing to the relatively low incidence of post-ERCP infectious complications in this group (2.8%), we were unable to identify any significant risk factors specific to this group (see Supplementary Figure S1, <http://links.lww.com/AJG/D41>).

Adverse events

There were no serious adverse events related to ERCP in either group, except for the primary, secondary, and other outcomes described above. There were no cases of anaphylaxis or serious allergic reactions to antibiotics (Pacetin) in the antibiotic prophylaxis group. There was no mortality from any causes in this trial.

DISCUSSION

In this large, single-center, double-blind, placebo-controlled, randomized trial, we found that the use of prophylactic antibiotics before ERCP in patients with biliary obstruction resulted in a

Table 3. Primary, secondary, and other outcomes

Variables	Antibiotic prophylaxis (N = 176)	Placebo (N = 173)	^a Risk ratio (95% CI)	P value
Primary outcome: Infectious complications after ERCP	5 (2.8)	17 (9.8)	0.29 (0.11–0.74)	**0.0073
Secondary outcomes				
Bacteremia	4 (2.3)	11 (6.4)	0.36 (0.12–1.04)	0.0599
Cholangitis	3 (1.7)	11 (6.4)	0.27 (0.08–0.87)	*0.0267
Cholecystitis	0 (0.0)	1 (0.6)	0.00 (0.00–3.76)	0.4957
Other outcomes				
Bleeding	1 (0.6)	2 (1.2)	0.49 (0.06–3.72)	0.6207
Pancreatitis	13 (7.4)	9 (5.2)	1.42 (0.64–3.17)	0.4012

Data are presented as n (%) or mean ± SD.

Two patients in the antibiotic prophylaxis group and 6 patients in the placebo group showed multiple infectious complications. Statistically significant values are indicated in bold and asterisk (*). ** $P < 0.01$; * $P < 0.05$.

ERCP, endoscopic retrograde cholangiopancreatography.

^aRisk ratios are presented for binary outcomes; values of less than 1 favor antibiotic prophylaxis.

significantly lower risk of infectious complications, especially cholangitis, than placebo. We found that prophylactic antibiotics lowered post-ERCP infectious complications regardless of the cause of biliary obstruction. Furthermore, even in cases of performing successful biliary drainage by ERCP, we found that the use of prophylactic antibiotics significantly lowered the incidence of infectious complications. Because there was no difference in the etiology or intervention between the antibiotic prophylaxis and placebo groups, this trial is considered suitable to demonstrate the efficacy of prophylactic antibiotics in patients with biliary obstruction.

Several randomized controlled studies have reported conflicting results regarding the efficacy of prophylactic antibiotics in ERCP. Although the biliary obstruction is a major risk factor for biliary infections and is also considered to be a risk factor for infectious complications after ERCP, the preventive effect of

prophylactic antibiotics has not been clearly demonstrated because large-scale prospective trials have not been conducted on patients with biliary obstruction. Under these circumstances, because 2 clinical factors, incomplete biliary drainage and severe neutropenia, have been reported to predict the benefit of antibiotic prophylaxis in patients undergoing ERCP (28,29), the current guidelines, including guidelines from the American Society for Gastrointestinal Endoscopy, European Society of Gastrointestinal Endoscopy, and British Society of Gastroenterology, do not recommend periprocedural antibiotic prophylaxis in ERCP, except in cases of anticipated incomplete biliary drainage and in severely immunocompromised patients. However, existing trials supporting the current guidelines were conducted decades ago and conducted on heterogeneous patient population. Here, we conducted a large-scale randomized trial with only patients with radiologically confirmed biliary obstruction but without overt infection. Our findings clearly demonstrate that the use of prophylactic antibiotics before ERCP significantly reduces the incidence of infectious complications, particularly bacteremia and cholangitis. Moreover, considering that most of the patients in our study (>90%) achieved complete biliary drainage, our results indicate that prophylactic antibiotics are beneficial not only for patients with anticipated incomplete biliary drainage but also for those with complete biliary drainage. These findings challenge the rationale behind recommending prophylactic antibiotics solely in cases of anticipated incomplete biliary drainage, as suggested by current guidelines.

The appropriate use of preprocedural prophylactic antibiotics is crucial for achieving favorable patient outcomes. However, it is important to exercise caution to avoid improper overuse of prophylactic antibiotics because they can contribute to the emergence of MDR bacterial infections within the community. Recent reports have indicated an increasing detection rate of MDR bacteria in cases of biliary infection, particularly among patients who received antibiotic prophylaxis before ERCP (30). Therefore, although our study provides evidence for the necessity of prophylactic antibiotics in patients with biliary obstruction, it is important to conduct multicenter randomized controlled trials including regions where ERCP-related MDR outbreaks have been

Table 4. Identified bacterial species in patients with bacteremia

Group	Species	N (%)
Antibiotic prophylaxis	Gram-negative bacteria	2 (50.0)
	<i>Escherichia coli</i>	1 (25.0)
	<i>Klebsiella pneumoniae</i>	1 (25.0)
	Gram-positive bacteria	3 (75.0)
	<i>Enterococcus faecalis</i>	3 (75.0)
Placebo	Gram-negative bacteria	7 (63.6)
	<i>Escherichia coli</i>	5 (45.5)
	<i>Klebsiella oxytoca</i>	2 (18.2)
	Gram-positive bacteria	7 (63.6)
	<i>Staphylococcus hominis</i>	1 (9.1)
	<i>Streptococcus sanguinis</i>	1 (9.1)
	<i>Streptococcus gallolyticus</i> subspecies <i>pasteurianus</i>	1 (9.1)
	<i>Enterococcus faecalis</i>	3 (27.3)
	<i>Enterococcus casseliflavus</i>	1 (9.1)

Data are presented as n (%).

In 1 patient in each group, 2 or more strains were detected.




Figure 2. Risk factor analysis for post-ERCP infectious complications. In the placebo group, clinical factors and procedure-related factors were included in the analysis. BD, bile duct; ERCP, endoscopic retrograde cholangiopancreatography; PA, peri-ampullary.

reported to establish general recommendations regarding the use of prophylactic antibiotics before ERCP in all patients with biliary obstruction.

In this trial, blood sampling for culture was performed on patients immediately after confirming their recovery from moderate sedation during the ERCP procedure. It is important to note that not all blood samples were obtained from patients at the exact same time interval after ERCP. Therefore, the rates of bacteremia could potentially vary depending on the timing of blood culture. However, most of the patients underwent blood sampling for culture within 2 hours after ERCP. Furthermore, there was no significant difference in the time interval of blood culture between the 2 groups and between patients with and without bacteremia. These findings suggest that the results would not have been significantly distorted because of differences in blood culture timing.

In addition, because the preprocedural blood sample was not obtained in this study, it was challenging to accurately differentiate whether the bacteremia identified in the post-ERCP blood culture was preexisting latent infection or developed as a result of the procedure. To minimize the possibility of latent infection, this study was conducted on patients who did not exhibit any signs or symptoms of infection within 72 hours before undergoing ERCP, considering the relatively short latent period of biliary infection. However, this inclusion criterion alone may not completely exclude the possibility of latent infection. Nonetheless, even if some patients have a latent infection from biliary obstruction before ERCP, the administration of preprocedural antibiotics can serve as a broad prophylactic measure to prevent latent infection from progressing to overt infection.

This study has several limitations. Although duodenoscope contamination is one of the etiologies of post-ERCP infection, any additional analyses to validate duodenoscope contamination or to identify specific strains associated with different etiologies were not performed in this study. Furthermore, this trial was large enough to demonstrate the clinical benefit of prophylactic antibiotics on preventing infectious complications after ERCP in patients with biliary obstruction, but not enough to demonstrate the preventive benefits in subgroups. Only 4 immunocompromised patients, taking immunosuppressive agents after liver

transplantation, were enrolled, and all of them were randomized to the antibiotic prophylaxis group. Among them, no patients suffered from infectious complications after ERCP; therefore, the effectiveness of prophylactic antibiotics in immunocompromised patients recommended by the existing guidelines could not be confirmed. In addition, this trial was conducted at a single medical center in Korea by several endoscopists, so there is a risk of ethnic bias or operator bias. However, because all registered patients have undergone ERCP at the same center, standardized intervention could be performed, and considering that the incidence of post-ERCP infectious complications in this trial was lower than previously reported incidence, the performed ERCP is considered to have been conducted by experienced endoscopy experts.

In conclusion, in this large, single-center, double-blind, placebo-controlled, randomized trial, we found that the use of prophylactic antibiotics with cefoxitin before ERCP in patients with biliary obstruction significantly lowered the incidence of infectious complications compared with the use of placebo regardless of the complete drainage of obstructed bile juice. This result conflicts with the existing guidelines suggesting antibiotic prophylaxis before ERCP only in cases of anticipated incomplete biliary drainage or in severely immunocompromised patients. We suggest reconsidering the use of prophylactic antibiotics when performing ERCP in patients with biliary obstruction.

CONFLICTS OF INTEREST

Guarantor of article: Moon Jae Chung, MD, PhD.

Specific author contributions: G.L., M.J.S., J.H.P., S.J.K., J.H.J., H.S.L., N.S.K., J.Y.P., S.B., S.W.P., S.Y.S., M.J.C.: conception and design. G.L., M.J.S., J.H.P., S.J.K., J.H.J., H.S.L., J.Y.P., S.B., M.J.C.: administrative support. G.L., M.J.S., J.H.P., S.J.K., J.H.J., H.S.L., J.Y.P., S.B., M.J.C.: provision of patients. G.L., M.J.S., J.H.P.: collection and assembly of data. G.L., M.J.S., J.H.P.: data analysis and interpretation. All authors: manuscript writing. All authors: Final approval of manuscript.

Financial support: The antibiotic used in this trial (Pacetin) was provided by JW Pharmaceutical, Seoul, Korea. No other funding sources were available.

Potential competing interests: The antibiotic used in this trial (Pacetin) was provided by JW Pharmaceutical, Seoul, Korea. However, this trial was designed and conducted independently of JW Pharmaceutical, and the authors declare no conflicts of interest.

Ethics approval and consent to participate: This study was approved by the Institutional Review Board of the Yonsei University Medical Center (number 4-2015-0596). All patients gave their written informed consent.

Data sharing: The trial protocol and deidentified participant data collected for this trial are available from the corresponding author M.J.C. on reasonable request.

Study Highlights

WHAT IS KNOWN

- ✓ The biliary obstruction is a major risk factor for biliary infections and is also considered to be a risk factor for infectious complications after endoscopic retrograde cholangiopancreatography, but the preventive effect of prophylactic antibiotics has not been clearly demonstrated because large-scale prospective trials have not been conducted on patients with biliary obstruction.

WHAT IS NEW HERE

- ✓ In this large, single-center, double-blind, placebo-controlled, randomized trial, we found that the use of prophylactic antibiotics with cefoxitin before endoscopic retrograde cholangiopancreatography in patients with biliary obstruction significantly lowered the incidence of infectious complications compared with the use of placebo regardless of the complete drainage of obstructed bile juice.

REFERENCES

1. Canakis A, Baron TH. Relief of biliary obstruction: Choosing between endoscopic ultrasound and endoscopic retrograde cholangiopancreatography. *BMJ Open Gastroenterol* 2020;7(1):e000428.
2. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: A systematic survey of prospective studies. *Am J Gastroenterol* 2007;102:1781–8.
3. Williams E, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP; results of a large—scale, prospective multicenter study. *Endoscopy* 2007;39(09):793–801.
4. Cotton PB, Connor P, Rawls E, et al. Infection after ERCP, and antibiotic prophylaxis: A sequential quality-improvement approach over 11 years. *Gastrointest Endosc* 2008;67(3):471–5.
5. Chandrasekhara V, Khashab MA, Muthusamy VR, et al. Adverse events associated with ERCP. *Gastrointest Endosc* 2017;85(1):32–47.
6. De Palma GD, Galloro G, Siciliano S, et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: Results of a prospective, randomized, and controlled study. *Gastrointest Endosc* 2001;53(6):547–53.
7. Nelson DB. Infectious disease complications of GI endoscopy: Part I, endogenous infections. *Gastrointest Endosc* 2003;57(4):546–56.
8. Park JS. Post-endoscopic retrograde cholangiopancreatography infection. *Korean J Pancreas Biliary Tract* 2017;22(1):24–34.
9. Rubin ZA, Kim S, Thaker AM, et al. Safely reprocessing duodenoscopes: Current evidence and future directions. *Lancet Gastroenterol Hepatol* 2018;3(7):499–508.
10. Larsen S, Russell RV, Ockert LK, et al. Rate and impact of duodenoscope contamination: A systematic review and meta-analysis. *EClinicalMedicine* 2020;25:100451.
11. Sauter G, Grabein B, Huber G, et al. Antibiotic prophylaxis of infectious complications with endoscopic retrograde cholangiopancreatography. A randomized controlled study. *Endoscopy* 1990;22(04):164–7.
12. Kullman E, Borch K, Lindstrom E, et al. Bacteremia following diagnostic and therapeutic ERCP. *Gastrointest Endosc* 1992;38(4):444–9.
13. Niederau C, Pohlmann U, Lübke H, et al. Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: Results of a randomized controlled clinical study. *Gastrointest Endosc* 1994;40(5):533–7.
14. Byl B, Deviere J, Struelens MJ, et al. Antibiotic prophylaxis for infectious complications after therapeutic endoscopic retrograde cholangiopancreatography: A randomized, double-blind, placebo-controlled study. *Clin Infect Dis* 1995;20(5):1236–40.
15. Bai Y, Gao F, Gao J, et al. Prophylactic antibiotics cannot prevent endoscopic retrograde cholangiopancreatography induced cholangitis A meta-analysis. *Pancreas* 2009;38(2):126–30.
16. van den Hazel SJ, Speelman P, Dankert J, et al. Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography. A randomized, controlled trial. *Ann Intern Med* 1996;125(6):442–7.
17. Rätty S, Pulkkinen M, Matikainen M, et al. Post-ERCP pancreatitis: Reduction by routine antibiotics. *J Gastrointest Surg* 2001;5(4):339–45.
18. Brand M, Bizos D, O'Farrell P Jr. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. *Cochrane Database Syst Rev* 2010(10):CD007345.
19. Allison MC, Sandoe JA, Tighe R, et al. Antibiotic prophylaxis in gastrointestinal endoscopy. *Gut* 2009;58(6):869–80.
20. Khashab MA, Chithadi KV, Acosta RD, et al. Antibiotic prophylaxis for GI endoscopy. *Gastrointest Endosc* 2015;81(1):81–9.
21. Dumonceau JM, Kapral C, Aabakken L, et al. ERCP-related adverse events: European society of gastrointestinal endoscopy (ESGE) guideline. *Endoscopy* 2020;52(2):127–49.
22. Sanders DJ, Bomman S, Krishnamoorthi R, et al. Endoscopic retrograde cholangiopancreatography: Current practice and future research. *World J Gastrointest Endosc* 2021;13(8):260–74.
23. Weber WP, Marti WR, Zwahlen M, et al. The timing of surgical antimicrobial prophylaxis. *Ann Surg* 2008;247(6):918–26.
24. Bratzler DW, Dellinger EP, Olsen Keith M, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm* 2013;70(3):195–283.
25. Nguyen HT, Bui QTH, Vo TV, et al. Antibiotic use in gastrointestinal surgery patients at a Vietnamese national hospital. *BMC Gastroenterol* 2022;22(1):480.
26. Mayumi T, Takada T, Kawarada Y, et al. Results of the Tokyo consensus meeting Tokyo guidelines. *J Hepatobiliary Pancreat Surg* 2007;14(1):114–21.
27. Thaker AM, Mosko JD, Berzin TM. Post-endoscopic retrograde cholangiopancreatography pancreatitis. *Gastroenterol Rep (Oxf)* 2015;3(1):32–40.
28. Bianco JA, Sullivan Pepe M, Higano C, et al. Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients. *AM J Med* 1990;89(2):134–6.
29. Motte S, Deviere J, Dumonceau JM, et al. Risk factors for septicemia following endoscopic biliary stenting. *Gastroenterology* 1991;101(5):1374–81.
30. Minami T, Sasaki T, Serikawa M, et al. Antibiotic prophylaxis for endoscopic retrograde cholangiopancreatography increases the detection rate of drug-resistant bacteria in bile. *J Hepatobiliary Pancreat Sci* 2014;21(9):712–8.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.